Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHAPSODY phase 3 study of rilonacept for recurrent pericarditis
2018-002719-87Phase 3Completed
- Sponsor
- Kiniksa Pharmaceuticals
- Start
- Jan 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilonacept in recurrent pericarditis (3 arms), sponsored by Kiniksa Pharmaceuticals. Primary endpoint: Time to pericarditis recurrence. Started Jan 2021; status: completed.
02
Drugs
rilonacept
03
Conditions
recurrent pericarditis
Beyond the preview
Go deeper on 2018-002719-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002719-87.